Mutations in the XNP/ATR-X gene, located in Xq13.3, are associated with several X linked mental retardation syndromes, the best known being thalassaemia with mental retardation (ATR-X). The XNP/ATR-X protein belongs to the family of SWI/SNF DNA helicases and contains three C2-C2 type zinc fingers of unknown function. Previous studies have shown that 65% of mutations of XNP have been found within the zinc finger domain (encoded by exons 7, 8, and the beginning of exon 9) while 35% of the mutations have been found in the helicase domain extending over 3 kb at the C-terminus of the protein. Although diVerent types of mutations have been identified, no specific genotypephenotype correlation has been found, suggesting that gene alteration leads to a loss of function irrespective of mutation type. Our aims were to understand the function of the XNP/ATR-X protein better, with specific attention to the functional consequences of mutations to the zinc finger domain. We used monoclonal antibodies directed against the XNP/ ATR-X protein and performed immunocytochemical and western blot analyses, which showed altered or absent XNP/ ATR-X expression in cells of aVected patients. In addition, we used in vitro experiments to show that the zinc finger domain can mediate double stranded DNA binding and found that the DNA binding capacity of mutant forms in ATR-X patients is severely reduced. These data provide insights into the understanding of the functional significance of XNP/ ATR-X mutations. (J Med Genet 2000;37:746-751) 
Mutations in the human XNP/ATR-X gene cause several mental retardation syndromes including thalassaemia with mental retardation (ATR-X), 1 Juberg-Marsidi syndrome, 2 Carpenter-Waziri syndrome, 3 Holmes-Gang syndrome (C Schwartz, personal communication), mental retardation with spastic paraplegia, 4 and mental retardation phenotypes without thalassaemia. 5 Despite the variability of phenotype associated with XNP/ ATR-X mutations, all male patients have a severe mental handicap associated with microcephaly and craniofacial dysmorphism. This suggests that this gene may be involved in brain development and facial morphogenesis. The XNP/ATR-X transcript encodes a predicted 2492 amino acid protein which harbours a nuclear localisation signal, three C 2 -C 2 zinc finger motifs, a coiled coil domain, and seven conserved "helicase" motifs found in DNA stimulated ATPase and DNA helicases of the SNF2/SWI2 protein family. [6] [7] [8] A high proportion (65%) of the mutations described so far are clustered in the zinc finger domain, 9 10 suggesting that this region of XNP/ATR-X is a functionally important region.
Although the precise function of XNP/ ATR-X remains to be elucidated, several lines of evidence suggest that it is involved in gene expression regulation via chromatin remodelling. First, we showed that the XNP/ATR-X protein participates in the formation of multiprotein complexes and is able to associate with the human EZH2 protein, 11 a human homologue of the Enhancer of zeste Drosophila gene involved in the regulation of homeotic gene expression through chromatin remodelling. 12 Second, a specific interaction has been identified between the mouse heterochromatin protein (HP1) and the mouse protein HP1-BP38, 13 a clone which has been shown to correspond to the mouse Xnp gene. 14 15 Recently, the interaction between XNP/ATR-X and HP1 has been confirmed by immunoprecipitation in human cells. 16 Lastly, it has been reported that XNP/ATR-X is a nuclear protein closely associated with the nuclear matrix at interphase and during mitosis the protein is found close to pericentromeric chromatin. 16 17 The aim of this study was to elucidate the function of XNP/ATR-X further, by analysing the consequence of mutations of the zinc finger domain in aVected patients. First, we studied the expression and subcellular localisation of the XNP/ATR-X protein using monoclonal antibodies directed against the XNP protein.
We then analysed the biochemical function of the zinc finger domain using a standard in vitro assay to evaluate DNA binding activity in controls and patients with mutations resulting in diVerent mutant proteins.
Materials and methods

PATIENTS
The three ATR-X male patients used in this study have been described previously. 7 10 These patients were selected for study on the basis of two criteria, (1) a classical ATR-X phenotype including severe mental retardation, microcephaly, characteristic facial dysmorphism (epicanthic folds, flat nasal bridge, small and triangular nose, anteverted nostrils, and a triangular mouth), hypotonia, and thalassaemia, and (2) mutations in the zinc finger domain of the XNP/ATR-X protein. The mutations in patients 1 and 3 are located in exons 8 and 7 of the XNP/ATR-X gene, respectively, causing replacement of an arginine by a cysteine residue (R246C) in patient 1, and a glycine by a glutamic acid residue (G175E) in patient 3. In patient 2, a mutation was found in exon 7 causing the splicing of 63 nucleotides coding for 21 amino acids (V178 to K198) and the maintenance of the open reading frame thereafter. RECOMBINANT fig  1B) . Second, immunoblotting experiments of total lymphoblastoid cell material show a band whose size is compatible with the size of the XNP/ATR-X open reading frame (about 280 kDa) and which is absent in extracts from ATR-X patients (see Results). Third, a cross reacting band of similar mobility was found in diVerent mouse tissues (data not shown).
CELL PREPARATIONS
Lymphoblastoid cells, grown in suspension, were washed in PBS, cytocentrifuged onto poly-L-lysin coated glass coverslips using a cytocentrifuge (200 rpm for 10 minutes, Cytospin2, Shandon), and fixed in 4% formaldehyde in PBS (pH 7.2) at room temperature for 15 minutes.
IMMUNOFLUORESCENCE STAINING
The cell preparations were treated as previously described. 19 After fixation, the cells were permeabilised with 0.1% triton X-100 in PBS for 15 minutes at room temperature. Nonspecific staining was blocked with 1% bovine 10 
Figure 1 Characterisation and specificity of the XNP/ATR-X antibody. (A) Schematic representation of the XNP/ATR-X gene showing the region corresponding to amino acid residues 321-884 of the protein used to generate the XNP-2H12 monoclonal antibody (indicated by the double arrow). (B) XNP-2H12 reacts eYciently with overexpressed XNP protein in yeast but not with another similarly produced control protein. (C) Total protein extracts obtained from lymphoblastoid cell lines of a normal subject and ATR-X patients resolved by SDS-PAGE, transferred to nitrocellulose membrane and probed with anti-XNP antibody. Two ATR-X patients (1 and 2) (patient 5, Villard et al
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serum albumin (BSA) in PBS for one hour before immunofluorescence staining. The cell preparations were incubated with monoclonal XNP antibody 2H12 (ascites fluid diluted 1:50 in PBS, 1% BSA) for one hour at room temperature. Following three consecutive five minute washes in PBS, cells were incubated for a further 30 minutes with Cy3 conjugated goat anti-mouse antibody at 1:40 dilution in PBS, 1% BSA. Slides were washed three times with PBS before counterstaining of nuclear DNA with Hoechst stain (10 mg/ml in PBS, three minutes) or DAPI stain (60 ng/ml, five minutes) and mounting in antifade solution (Vectashield). Preparations were observed under a fluorescence microscope (Zeiss Axioplan 2) with 100 × magnification. The images were captured with a CCD camera (photometrics Sensys) treated using IPLab spectrum software (Vysis).
IN VITRO BINDING ASSAYS
The following oligonucleotide pairs, XNP dh11 (CCAGTGCTGAATGAAGACAAAGATG) and XNP 5'R (GTGCGGAATAAGAGTAG-GTTAC), were used to amplify by PCR XNP exons 7 to 9 (accession number U75653) which were cloned into vector pRSET C (Invitrogen). Sequence integrity of the amplified fragment was checked before use. DNA binding was assayed using radiolabelled protein fragments corresponding to aa 131-338 from either wild type XNP/ATR-X protein or from XNP protein found in ATR-X patients and generated using the T7 translation transcription (TnT) rabbit reticulocyte lysate system (Promega) with translation grade [ A total of 50 µg of single stranded DNA or double stranded DNA from calf thymus coupled to agarose beads (SIGMA) were reacted with TnT XNP in 0.5 ml of binding buVer (50 mmol/l NaCl, 50 mmol/l Tris (pH 7.5), 2 mmol/l DTT, 2.5 mmol/l MgCl 2 , 0.2% Nonidet P-40) for one hour at 4°C. The bound fraction was then rinsed five times at 4°C for 10 minutes in 1 ml of prechilled binding buVer supplemented with NaCl. Bound radiolabelled fractions were finally released from the agarose beads by boiling in SDS dye and resolved by 15% SDS-PAGE. To prevent artefactual results, binding experiments were independently repeated twice.
Results
EXPRESSION OF THE XNP/ATR-X PROTEIN IN PATHOLOGICAL CELLS
We raised a monoclonal antibody (XNP-2H12) against a fusion protein corresponding to amino acid residues 321-884 of the XNP protein ( fig  1A) and showed that this antibody specifically recognised the XNP protein. Using immunoblot analysis, we showed that the monoclonal antibody XNP-2H12 reacts eYciently with overexpressed XNP protein in yeast but not with another similarly produced control protein ( fig  1B) . By western blot experiments of total lymphoblastoid cell material, we showed a band in the normal control whose size was compatible with the size of the XNP open reading frame (about 280 kDa) ( fig 1C) . We then tested the protein expression in lymphocytes from three ATR-X patients described above. As shown in fig 1C , patient 1 with a missense mutation described above as a " hot spot" mutation in the zinc finger domain (R246C), 10 and patient 2 carrying a deletion of 63 bp ( V178-K198), 7 10 did not show a band of the correct size on western blotting, suggesting degradation or instability of the protein. Patient 3 (G175E) 10 showed one band of the correct size, but with a reduced intensity and another band corresponding to a unknown 180 kDa product.
SUBCELLULAR LOCALISATION OF THE XNP/ATR-X MUTANT PROTEIN
Considering that the subcellular localisation of transcription factors is essential for their biological activity, we speculated whether an abnormal subcellular distribution of mutant XNP/ATR-X proteins could account for the disease. To address this issue, the localisation of XNP protein in cells from ATR-X patients was examined by immunofluorescence microscopy. As previously described, 16 17 we found that in control cells XNP/ATR-X localises exclusively to the nucleus and is mainly concentrated in interphase into large discrete foci that vary in number (between two and 15 per nucleus) and size (fig 2A) . Similar profiles
Figure 2 Alteration of the distribution of the XNP/ATR-X protein in lymphoblastoid cells of the patients. Lymphocytes from a normal subject and from ATR-X patients were immunolabelled with XNP antibody (red signals). Cell nuclei are shown enlarged × 2000 (20 mm=10 µm). In a normal control, XNP/ATR-X protein localised exclusively within the nucleus, with discrete foci of intense staining numbering between two to 15 per nucleus (A). The same experiments were performed on lymphocytes of previously reported XNP missense mutations in the zinc finger domain, R246C (B) and G175E (D), and a 21 amino acid deletion V178-K198 (C) showed either absence or a modified pattern of nuclear location.
of staining were obtained with fibroblasts cells during interphase (data not shown).
In contrast to the wild type, mutated XNP/ ATR-X protein showed a drastically altered cellular distribution pattern ( fig 2B, C, D) . The number of intense nuclear dots was severely decreased in cells from the patient with a deletion of 63 bp ( V178-K198) in the zinc finger domain (fig 2C) . In cells from patients with missense mutations R246C or G175E, a speckled pattern of organisation could not be distinguished and a diVuse XNP/ATR-X staining was observed (fig 2B, D) . A few cells showed a more surprising pattern with staining showing cytoplasmic perinuclear signals.
THE ZINC FINGER DOMAIN CAN BIND DNA IN VITRO AND THIS ACTIVITY IS ABOLISHED IN SEVERAL MUTANT PROTEINS
Zinc finger domains have been associated with either DNA binding activity or protein/protein interactions (PHD fingers). To discriminate between these two possibilities, we investigated if XNP could directly bind DNA using an in vitro assay. DiYculties in overexpression of the proteic region corresponding to the zinc finger domains in E coli or in yeast compelled us to synthesise 35 S-radiolabelled peptides corresponding to the three C2-C2 zinc finger motifs (aa 131-338) using a coupled transcription translation system in rabbit reticulocytes (TnT). These synthetic peptides were then assayed for their ability to bind DNA homopolymers coupled with agarose. 20 21 As shown in fig 3A, we found that XNP/ATR-X peptide associates very eYciently with DNA.
Figure 3 In vitro DNA binding assays of wild type and mutant XNP/ATR-X protein. Five percent (30 000 cpm) of the TnT added to each binding reaction is shown on the left of the panel (input). Bound fractions remaining after washes in 100, 250, or 500 mmol/l NaCl were resolved by 15% SDS-PAGE. The two XNP/ATR-X species observed are probably the result of either an internal initiation event or premature termination. Binding assay was performed as described above using in vitro generated wild type XNP/ATR-X: control (A) and mutated XNP/ATR-X protein with a missense mutation G175E (B) or with a 21 amino acid deletion V178-K198 (C). (D) Quantification of the double strand DNA binding activity of the normal and mutant proteins
To study the eVect of ionic strength on the stability of the XNP/DNA interaction, protein bound to the single stranded (ss) or double stranded (ds) DNA was washed in a buVer with increasing NaCl concentrations (100, 250, and 500 mmol/l). Association with ss-DNA was detected only when low stringency washing conditions were used, probably ruling out the potential in vivo binding capacity of this domain to ss-DNA. However, we found that binding to ds-DNA was still detectable at 500 mmol/l NaCl, suggesting that hydrophobic interactions rather than ionic contacts may be involved in the formation of the XNP/DNA complex. XNP/ATR-X is therefore, at least in vitro, a DNA binding protein and this activity is mediated by the zinc finger region. Most of the mutations detected in patients aVect the zinc finger domain. To investigate whether these mutations aVected the DNA binding capacities of the corresponding XNP/ ATR-X protein, we cloned two mutated domains originating from two patients and synthesised the corresponding 35 S radiolabelled peptides, as described above. One missense mutation (G175E) and one deletion mutation ( V178-K198) were tested. Equivalent amounts of in vitro generated wild type or mutated protein fragments were incubated with single or double stranded DNA cellulose, and bound fractions were analysed as described above (fig 3B, C) . The data shown in fig 3D indicate that all mutations result in decreased binding eYciency. The deletion of 21 amino acids in the first zinc finger ( V178-K198) as well as introduction of the G175E missense mutation almost completely abolish the in vitro DNA binding capacity.
Discussion
Mutations in the XNP/ATR-X gene have been associated with a large and varied group of X linked mental retardation syndromes with associated anomalies in multiple systems, suggesting its importance as a fundamental regulatory component in multiple tissues during development. XNP is a large gene (7 kb of ORF) but most mutations detected in familial ATR-X cases and related syndromes are clustered in a 300 bp region, encoding three putative zinc fingers. 7 This region is also frequently mutated in sporadic ATR-X cases. 10 In this study, we have shown by western blot and immunocytochemical analysis an altered or absent expression of the XNP protein in ATR-X patients with mutations of the zinc finger domain. These domains are classically involved in DNA binding activity, yet it has been proposed that the XNP/ATR-X zinc fingers are homologous to those present in plant homeodomain (PHD) finger domains, 9 a structure known to be involved in protein/ protein interactions. 22 Results obtained with normal controls show localisation of the XNP/ATR-X protein to the nucleus where it is concentrated in a distinct speckled pattern. This is consistent with recent findings showing XNP/ATR-X to be a nuclear protein associated with pericentromeric heterochromatin during interphase and mitosis. 16 17 In addition, our findings show that in cells from ATR-X patients with missense mutations or deletions of the zinc finger domain, the XNP protein is mislocalised. This is a similar finding to that of mutants with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED), who lack PHD domains and consequently show an altered subcellular distribution of AIRE protein fragments. 23 24 In both disorders, however, the exact mechanism of protein mislocalisation is uncertain, and may be a consequence of failure of protein-protein interaction or a failure of DNA binding activity.
In regard to this question, we and others have previously been unable to find mutations or deletions in ATR-X patients in the domain of protein-protein interaction (aa 321-1201), which is close to the zinc finger domain. Our previous studies using a two hybrid screen failed to show an interaction between proteins associated with heterochromatin and the zinc finger domain. 11 In addition, it has recently been shown that mutations in ATR-X patients can cause a change in the pattern of methylation of several repeated sequences including ribosomic DNA, a Y specific sequence, and subtelomeric repeats. 25 This may suggest a link between the methylation machinery and the multiprotein complex containing the XNP/ ATR-X protein and thus a role of XNP/ATR-X in the recognition and expression of specific genes (such as the globin gene).
In the present study, we addressed this question further by performing in vitro binding experiments to study the potential nucleic acid binding properties of the XNP/ATR-X protein.
We showed that the zinc finger region is suYcient to bind double stranded DNA in vitro with strong aYnity, suggesting that XNP could be a DNA binding protein. DNA binding properties of SWI/SNF complexes have already been reported 25 for members of the CHD subfamily, which exhibit both helicase/ATPase domains and a DNA binding domain. 26 However, XNP is the only member of the SWI/SNF family known to contain a zinc finger domain for which DNA binding activity has been documented.
These results are derived from in vitro studies. Support for our hypothesis of impaired DNA binding in patients with XNP/ATRX mutations will require further experiments using purified XNP/ATR-X protein to show that XNP binds DNA in vivo. Owing to the size of the XNP/ATR-X protein, such experiments are technically diYcult using available methods. The data presented here describe only non-sequence specific DNA binding and characterisation of DNA recognition motifs is currently being investigated to identify genes targeted to XNP/ATR-X regulation. However, despite these limitations, the reduced DNA binding activity shown in our patients with XNP missense and deletion mutations supports the hypothesis that nucleic acid binding by XNP/ATR-X is functionally significant.
Although compelling evidence now exists that diVerent types of mutations in the XNP/ATR-X gene account for common clinical features, the precise biological basis of the phenotype observed in ATR-X patients is yet to be elucidated. The present study was thus undertaken to determine how mutations in the XNP/ATR-X gene may aVect protein function. For this, we first investigated the subcellular localisation of mutant XNP/ATR-X proteins and found that the cellular distribution of the mutant protein present in ATR-X patients is severely aVected. Secondly, we produced a series of recombinant proteins carrying mutations identified in ATR-X patients and tested these proteins for DNA binding. We found that most mutations in the zinc finger domain alter DNA binding. We thus conclude that an alteration of DNA binding is probably the major abnormal biochemical mechanism leading to pathogenicity. Whether the same situation exists for mutations located outside the zinc finger domain, particularly for mutations in the helicase domain, is currently under investigation.
We thank the patients, families, and clinicians for their collaboration. We are grateful to R J Leventer, J L Mandel, D Devys, and L Villard for critical reading of the manuscript and helpful discussions. We also thank the AFM/AP-HM Cell, DNA library, and C E Schwartz who provided ATR-X patient specimens. These studies were funded by grants from the Institut National de la Sante et de la Recherche Medicale and from the Association pour la Recherche contre le Cancer.
